Cavitary penetration of levofloxacin among patients with multidrug-resistant tuberculosis. 2015

Russell R Kempker, and Aline B Barth, and Sergo Vashakidze, and Ketino Nikolaishvili, and Irina Sabulua, and Nestani Tukvadze, and Nino Bablishvili, and Shota Gogishvili, and Ravi Shankar P Singh, and Jeannette Guarner, and Hartmut Derendorf, and Charles A Peloquin, and Henry M Blumberg
Division of Infectious Diseases Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA rkempke@emory.edu.

A better understanding of second-line drug (SLD) pharmacokinetics, including cavitary penetration, may help optimize SLD dosing. Patients with pulmonary multidrug-resistant tuberculosis (MDR-TB) undergoing adjunctive surgery were enrolled in Tbilisi, Georgia. Serum was obtained at 0, 1, 4, and 8 h and at the time of cavitary removal to measure levofloxacin concentrations. After surgery, microdialysis was performed using the ex vivo cavity, and levofloxacin concentrations in the collected dialysate fluid were measured. Noncompartmental analysis was performed, and a cavitary-to-serum levofloxacin concentration ratio was calculated. Twelve patients received levofloxacin for a median of 373 days before surgery (median dose, 11.8 mg/kg). The median levofloxacin concentration in serum (Cmax) was 6.5 μg/ml, and it was <2 μg/ml in 3 (25%) patients. Among 11 patients with complete data, the median cavitary concentration of levofloxacin was 4.36 μg/ml (range, 0.46 to 8.82). The median cavitary/serum levofloxacin ratio was 1.33 (range, 0.63 to 2.36), and 7 patients (64%) had a ratio of >1. There was a significant correlation between serum and cavitary concentrations (r = 0.71; P = 0.01). Levofloxacin had excellent penetration into chronic cavitary TB lesions, and there was a good correlation between serum and cavitary concentrations. Optimizing serum concentrations will help ensure optimal cavitary concentrations of levofloxacin, which may enhance treatment outcomes.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D055815 Young Adult A person between 19 and 24 years of age. Adult, Young,Adults, Young,Young Adults
D018088 Tuberculosis, Multidrug-Resistant Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS. Tuberculosis, Drug-Resistant,Tuberculosis, MDR,Tuberculosis, Multi-Drug Resistant,Drug-Resistant Tuberculosis,MDR Tuberculosis,Multi-Drug Resistant Tuberculosis,Multidrug-Resistant Tuberculosis,Tuberculosis, Drug Resistant,Tuberculosis, Multi Drug Resistant,Tuberculosis, Multidrug Resistant
D064704 Levofloxacin The L-isomer of Ofloxacin. Levaquin,Levofloxacin Anhydrous,Ofloxacin, (S)-Isomer,Quixin,Anhydrous, Levofloxacin

Related Publications

Russell R Kempker, and Aline B Barth, and Sergo Vashakidze, and Ketino Nikolaishvili, and Irina Sabulua, and Nestani Tukvadze, and Nino Bablishvili, and Shota Gogishvili, and Ravi Shankar P Singh, and Jeannette Guarner, and Hartmut Derendorf, and Charles A Peloquin, and Henry M Blumberg
December 2021, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery,
Russell R Kempker, and Aline B Barth, and Sergo Vashakidze, and Ketino Nikolaishvili, and Irina Sabulua, and Nestani Tukvadze, and Nino Bablishvili, and Shota Gogishvili, and Ravi Shankar P Singh, and Jeannette Guarner, and Hartmut Derendorf, and Charles A Peloquin, and Henry M Blumberg
April 2019, The European respiratory journal,
Russell R Kempker, and Aline B Barth, and Sergo Vashakidze, and Ketino Nikolaishvili, and Irina Sabulua, and Nestani Tukvadze, and Nino Bablishvili, and Shota Gogishvili, and Ravi Shankar P Singh, and Jeannette Guarner, and Hartmut Derendorf, and Charles A Peloquin, and Henry M Blumberg
August 2017, Antimicrobial agents and chemotherapy,
Russell R Kempker, and Aline B Barth, and Sergo Vashakidze, and Ketino Nikolaishvili, and Irina Sabulua, and Nestani Tukvadze, and Nino Bablishvili, and Shota Gogishvili, and Ravi Shankar P Singh, and Jeannette Guarner, and Hartmut Derendorf, and Charles A Peloquin, and Henry M Blumberg
March 2000, Chest,
Russell R Kempker, and Aline B Barth, and Sergo Vashakidze, and Ketino Nikolaishvili, and Irina Sabulua, and Nestani Tukvadze, and Nino Bablishvili, and Shota Gogishvili, and Ravi Shankar P Singh, and Jeannette Guarner, and Hartmut Derendorf, and Charles A Peloquin, and Henry M Blumberg
April 2010, The Lancet. Infectious diseases,
Russell R Kempker, and Aline B Barth, and Sergo Vashakidze, and Ketino Nikolaishvili, and Irina Sabulua, and Nestani Tukvadze, and Nino Bablishvili, and Shota Gogishvili, and Ravi Shankar P Singh, and Jeannette Guarner, and Hartmut Derendorf, and Charles A Peloquin, and Henry M Blumberg
October 2013, American journal of respiratory and critical care medicine,
Russell R Kempker, and Aline B Barth, and Sergo Vashakidze, and Ketino Nikolaishvili, and Irina Sabulua, and Nestani Tukvadze, and Nino Bablishvili, and Shota Gogishvili, and Ravi Shankar P Singh, and Jeannette Guarner, and Hartmut Derendorf, and Charles A Peloquin, and Henry M Blumberg
May 2012, Medicina clinica,
Russell R Kempker, and Aline B Barth, and Sergo Vashakidze, and Ketino Nikolaishvili, and Irina Sabulua, and Nestani Tukvadze, and Nino Bablishvili, and Shota Gogishvili, and Ravi Shankar P Singh, and Jeannette Guarner, and Hartmut Derendorf, and Charles A Peloquin, and Henry M Blumberg
March 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery,
Russell R Kempker, and Aline B Barth, and Sergo Vashakidze, and Ketino Nikolaishvili, and Irina Sabulua, and Nestani Tukvadze, and Nino Bablishvili, and Shota Gogishvili, and Ravi Shankar P Singh, and Jeannette Guarner, and Hartmut Derendorf, and Charles A Peloquin, and Henry M Blumberg
October 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease,
Russell R Kempker, and Aline B Barth, and Sergo Vashakidze, and Ketino Nikolaishvili, and Irina Sabulua, and Nestani Tukvadze, and Nino Bablishvili, and Shota Gogishvili, and Ravi Shankar P Singh, and Jeannette Guarner, and Hartmut Derendorf, and Charles A Peloquin, and Henry M Blumberg
March 2011, The Indian journal of medical research,
Copied contents to your clipboard!